Patents by Inventor Kevin Kelnar

Kevin Kelnar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20150284719
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: June 12, 2015
    Publication date: October 8, 2015
    Inventors: David BROWN, Lance FORD, Angie CHENG, Rich JARVIS, Mike BYROM, Dmitriy OVCHARENKO, Eric DEVROE, Kevin KELNAR
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20150284720
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: June 12, 2015
    Publication date: October 8, 2015
    Inventors: David BROWN, Lance FORD, Angie CHENG, Rich JARVIS, Mike BYROM, Dmitriy OVCHARENKO, Eric DEVROE, Kevin KELNAR
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20150275213
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: June 9, 2015
    Publication date: October 1, 2015
    Inventors: David BROWN, Lance FORD, Angie CHENG, Rich JARVIS, Mike BYROM, Dmitriy OVCHARENKO, Eric DEVROE, Kevin KELNAR
  • COMBINATION CANCER TREATMENTS UTILIZING MICRORNAS AND EGFR-TKI INHIBITORS
    Publication number: 20150272981
    Abstract: The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a microRNA.
    Type: Application
    Filed: June 10, 2015
    Publication date: October 1, 2015
    Inventors: Andreas BADER, Jane ZHAO, Kevin KELNAR
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 9068219
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: June 30, 2015
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 9051571
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: June 9, 2015
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8946177
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 3, 2015
    Assignee: Mima Therapeutics, Inc
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20150004221
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: January 1, 2015
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20150005366
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: January 1, 2015
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140348907
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140350086
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140348908
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140314833
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Mirna Therapeutics, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • COMBINATION CANCER TREATMENTS UTILIZING SYNTHETIC OLIGONUCLEOTIDES AND EGFR-TKI INHIBITORS
    Publication number: 20140308274
    Abstract: The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a synthetic oligonucleotide.
    Type: Application
    Filed: March 17, 2014
    Publication date: October 16, 2014
    Applicant: MIRNA THERAPEUTICS, INC.
    Inventors: Andreas Bader, Jane Zhao, Kevin Kelnar
  • COMBINATION CANCER TREATMENTS UTILIZING MICRORNAS AND EGFR-TKI INHIBITORS
    Publication number: 20140309278
    Abstract: The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a microRNA.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 16, 2014
    Applicant: MIRNA THERAPEUTICS, INC.
    Inventors: ANDREAS BADER, JANE ZHAO, KEVIN KELNAR
  • MIRNA BIOMARKERS OF PROSTATE DISEASE
    Publication number: 20140235469
    Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.
    Type: Application
    Filed: October 28, 2013
    Publication date: August 21, 2014
    Applicant: ASURAGEN, INC.
    Inventors: Jeffrey SHELTON, Kevin KELNAR, Stephanie VOLZ, Alex ADAI, David BROWN
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8765709
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 1, 2014
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • SYNTHETIC MIMICS OF MIR-34
    Publication number: 20140107182
    Abstract: Embodiments concern methods and compositions involving miR-34 mimics, including miR-34a and miR-34c mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34a sequence and a complementary passenger strand. In additional embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34c sequence and a complementary passenger strand.
    Type: Application
    Filed: November 15, 2013
    Publication date: April 17, 2014
    Applicant: Mirna Therapeutics, Inc.
    Inventors: Kevin Kelnar, David Brown
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140031415
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 28, 2013
    Publication date: January 30, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • MiRNA biomarkers of prostate disease
    Patent number: 8597892
    Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: December 3, 2013
    Assignee: Asuragen, Inc.
    Inventors: Jeffrey Shelton, Kevin Kelnar, Stephanie Volz, Alex Adai, David Brown